Triple Hair Group receives Health Canada approval to start Phase III clinical trials on its Therapy-07 prescription drug in Canada
28 juin 2023 07h00 HE
|
Triple Hair Inc.
MONTRÉAL, June 28, 2023 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (“Triple Hair” or the “Company”), a global leader in the development of innovative treatments for alopecia, is pleased to...
Triple Hair Group reçoit l'approbation de Santé Canada pour commencer les essais cliniques de phase III sur son médicament sur ordonnance Thérapie-07 au Canada
28 juin 2023 07h00 HE
|
Triple Hair Inc.
MONTRÉAL, 28 juin 2023 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (« Triple Hair » ou la « Société »), un leader mondial dans le développement de traitements novateurs contre l'alopécie, a le...
Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium
06 oct. 2022 23h39 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Results from Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical)’s successful Phase 3 study (AIRFLO) with the respiratory syncytial...
爱科百发在第12届国际呼吸道合胞病毒（RSV）年会上报告了爱司韦™在RSV感染的住院婴幼儿中的三期临床试验（AIRFLO）积极结果
06 oct. 2022 23h39 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中国上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
愛科百發在第12屆國際呼吸道合胞病毒（RSV）年會上報告了愛司韋™在RSV感染的住院嬰幼兒中的三期臨床試驗（AIRFLO）積極結果
06 oct. 2022 23h39 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中國上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
20 sept. 2022 21h31 HE
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)
14 févr. 2022 07h30 HE
|
Arch Biopartners
TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection
25 janv. 2022 05h06 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir...
爱科百发宣布完成抗呼吸道合胞病毒新药齐瑞索韦的III期临床试验全部患者入组和用药治疗
25 janv. 2022 05h06 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) --...
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
10 juin 2021 07h20 HE
|
Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...